Regeneron Pharmaceuticals Inc. said its monoclonal antibody drug continued to provide strong protection against Covid-19 infection for eight months, reducing the risk of contracting the disease by 81.6% compared with a placebo in a long-term study.
Regeneron said on Monday that the data show the drug, called REGEN-COV, can provide long-lasting temporary immunity against Covid-19, which could make it an attractive option for people who don’t respond to vaccines because they have impaired immune systems.
